GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (NAS:LIXT) » Definitions » EBIT per Share

LIXT (Lixte Biotechnology Holdings) EBIT per Share : $-1.82 (TTM As of Jun. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Lixte Biotechnology Holdings EBIT per Share?

Lixte Biotechnology Holdings's EBIT per Share for the three months ended in Jun. 2024 was $-0.45. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $-1.82.

During the past 3 years, the average EBIT per Share Growth Rate was 2.80% per year. During the past 5 years, the average EBIT per Share Growth Rate was -9.80% per year. During the past 10 years, the average EBIT per Share Growth Rate was -3.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Lixte Biotechnology Holdings's EBIT per Share or its related term are showing as below:

LIXT' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -55.2   Med: -3.35   Max: 25.8
Current: 2.8

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Lixte Biotechnology Holdings was 25.80% per year. The lowest was -55.20% per year. And the median was -3.35% per year.

LIXT's 3-Year EBIT Growth Rate is ranked worse than
50.36% of 1257 companies
in the Biotechnology industry
Industry Median: 3.2 vs LIXT: 2.80

Lixte Biotechnology Holdings's EBIT for the three months ended in Jun. 2024 was $-1.01 Mil.


Lixte Biotechnology Holdings EBIT per Share Historical Data

The historical data trend for Lixte Biotechnology Holdings's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings EBIT per Share Chart

Lixte Biotechnology Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.18 -2.89 -4.99 -3.99 -2.65

Lixte Biotechnology Holdings Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.00 -0.49 -0.45 -0.43 -0.45

Lixte Biotechnology Holdings EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Lixte Biotechnology Holdings's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBIT per Share(A: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-5.071/1.916
=-2.65

Lixte Biotechnology Holdings's EBIT per Share for the quarter that ended in Jun. 2024 is calculated as

EBIT per Share(Q: Jun. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-1.007/2.249
=-0.45

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lixte Biotechnology Holdings  (NAS:LIXT) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.


Lixte Biotechnology Holdings EBIT per Share Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Lixte Biotechnology Holdings Business Description

Traded in Other Exchanges
N/A
Address
680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
Executives
Rene Bernards director KONINGSVAREN 37, ABCOUDE P7 1391AD
Van Der Baan Bastiaan Jeroen director HOGEWEG 4-H, AMSTERDAM P7 1098CB
Eric Forman 10 percent owner 117 E. 29TH ST., APT. 5A, NEW YORK NY 10016
Regina Brown director 248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733
Glenn Krinsky 10 percent owner C/O SRKP 1, INC., 1900 AVENUE OF THE STARS, SUITE 310, LOS ANGELES CA 90067
Yun Yen director 1301 OAKLAWN ROAD, ARCADIA CA 91006
Robert Greenberg 10 percent owner SKECHERS USA INC, 228 MANHATTAN BEACH BLVD, MANHATTAN BEACH CA 90266
Gil Schwartzberg 10 percent owner 269 S. BEVERLY DR., #1315, BEVERLY HILLS CA 90212
Philip F Palmedo director 1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067
John S Kovach director, 10 percent owner, officer: Pres., CFO & Secty 1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067
Stephen J. Forman director 248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733
Hung Tak Ho 10 percent owner MAYFAIR BY THE SEA II, TOWER T8, 1/F, UNIT A, 21 FO CHUN ROAD, PAK SHEK KOK, TAIPO K3 00000
Robert N Weingarten officer: Vice President and CFO 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367
James Miser officer: Chief Medical Officer 680 E COLORADO BLVD., SUITE 180, PASADENA CA 91101
Jane Merrill Riggs 10 percent owner 4852 SAINT ANDRES AVENUE, LA VERNE CA 91750

Lixte Biotechnology Holdings Headlines

From GuruFocus